Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Cancer Res. 2014 Nov 28;75(5):880–891. doi: 10.1158/0008-5472.CAN-14-0573

Figure 4. Combination of FGFR-inhibitor or MAPK-pathway inhibitors with imatinib restores sensitivity in GIST 10R cells.

Figure 4

A, GIST 10R cells were treated with combinations of imatinib with PD173074 (FGFR inhibitor; 1:1 ratio). Cells were cultured in drug dilutions for 48 h and viability was quantified by MTS assay. B, Combination indices were calculated for each concentration point of each drug curve. Asterisks mark combinations that show significant synergy (upper limit of interaction index below 1). C, GIST 10R cells were treated with combinations of imatinib with AZD-6244 (MEK inhibitor; 1:1 ratio). Cells were cultured in drug dilutions for 48 h and viability was quantified by MTS assay. D, GIST 10R cells were treated with combinations of imatinib with PI103 (PI3K inhibitor; 1:10 ratio). Cells were cultured in drug dilutions for 48 h and viability was quantified by MTS assay.